Business Standard

Divi's Lab surges 15%, hits fresh 52-week high on robust Q1 earnings

The company reported a net profit of Rs 492.06 crore for the quarter

stocks, BSE Bankex
Premium

Motilal Oswal has upgraded the stock to buy with the target price of Rs 3,350

SI Reporter New Delhi
Shares of Divi's Laboratories on Monday zoomed 15 per cent to a fresh 52-week high of Rs 3,201.85 on the BSE after reporting 80.61 per cent year-on-year (YoY) rise in consolidated net profit for the June quarter of 2020-21 (Q1FY21). 

The drug firm reported a net profit of Rs 492.06 crore for the quarter on account of robust sales. In comparison, the company had logged a profit of Rs 272.44 crore in the year-ago same period, Divi's Laboratories said in a filing to BSE.

Total income stood at Rs 1,747.80 crore during the quarter under review as against Rs 1,193.20 crore in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in